Business Context and Reporting Period
Company: Capstone Therapeutics Corp. (formerly OrthoLogic Corp.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2010
Business Overview: A development-stage biotechnology company focused on two product platforms: AZX100 (a peptide for scarring and pulmonary fibrosis) and Chrysalin (a peptide for tissue repair and vascular health). The company sold its former bone device business in 2003 and currently has no revenue-generating operations.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2010 | Nine Months Ended Sep 30, 2010 | As of Sep 30, 2010 |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(2,581,000) | $(8,455,000) | N/A |
| Loss Per Share (Basic/Diluted) | $(0.06) | $(0.21) | N/A |
| Operating Expenses | $(2,609,000) | $(8,554,000) | N/A |
| Cash and Cash Equivalents | N/A | N/A | $11,693,000 |
| Short-Term Investments | N/A | N/A | $15,467,000 |
| Total Current Assets | N/A | N/A | $27,579,000 |
| Total Current Liabilities | N/A | N/A | $1,408,000 |
| Potentially Redeemable Equity | N/A | N/A | $15,603,000 |
| Accumulated Deficit | N/A | N/A | $(177,993,000) |
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by approximately $0.7 million for the three months ended September 30, 2010, compared to the same period in 2009. For the nine-month period, the loss decreased by $2.1 million.
- Expense Drivers: The reduction in loss is primarily attributed to decreased Research and Development (R&D) expenses. R&D costs dropped from $2.84 million to $1.91 million (quarterly) and from $9.03 million to $6.09 million (nine-month). This is due to the completion of study initiation, surgeries, and dosing for Phase 2 clinical trials in 2009, with 2010 costs limited to monitoring and data analysis.
- Interest Income Decline: Interest and other income decreased significantly due to lower interest rates and a reduction in the amount of cash available for investment.
- Balance Sheet Reclassification: A significant portion of accumulated deficit was reclassified to "Potentially Redeemable Equity" ($15.6 million) to reflect the potential redemption obligation associated with shareholder put rights approved in May 2010.
Outlook, Risks, and Management Commentary
- Clinical Progress: The company expects to complete and report results for keloid scarring studies and substantially complete the Phase 2 trial for dermal scarring following shoulder surgery in 2010. Pre-clinical studies for AZX100 will continue.
- Strategic Shift for Chrysalin: Management has shifted strategy for Chrysalin from independent clinical trials to pursuing development partnering, collaboration, or licensing opportunities.
- Liquidity: Management anticipates that current cash and short-term investments ($27.2 million total) are sufficient to meet projected requirements for the next year. However, additional capital will be required to complete clinical trials and obtain FDA approval.
- Put Rights Risk: Shareholders approved "put rights" exercisable on or about July 31, 2011, allowing them to sell shares back to the company at a formula-based price (approx. 90% of available cash per share). The exercise of these rights could materially impact liquidity and the ability to continue operations.
- Legal Proceedings: The company is defending a qui tam complaint regarding its former bone device business (sold in 2003). Management believes the resolution will not have a material adverse effect.
Investor Verification Checklist
- Cash Runway: Verify if the $27.2 million in liquid assets is sufficient to fund operations through the completion of AZX100 Phase 2 trials and the potential exercise of put rights in mid-2011.
- Put Rights Impact: Assess the potential cash outflow if a significant portion of the 40.8 million outstanding shares are tendered under the put right provision in July 2011.
- Clinical Milestones: Monitor the upcoming release of Phase 2 data for AZX100 in keloid and dermal scarring, which is critical for future valuation or partnership deals.
- Partnership Status: Track progress on securing a partner for Chrysalin, as the company has ceased independent clinical development for this asset.
- Legal Exposure: Review the status of the pending motion to dismiss the False Claims Act lawsuit regarding the legacy bone device business.